---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010964"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:18:33.724163+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NeuroBo signs joint research agreement for once-monthly obesity therapy DA-1726

## Summary
- Collaboration with Dong-A ST and ImmunoForge to develop long-acting formulation of GLP1R/GCGR dual agonist DA-1726.
- ImmunoForge's ELP platform can extend drug half-life up to 200x, enabling once-monthly injection.
- DA-1726 currently in Phase 1; financial terms of the agreement not disclosed.
- Goal is to improve patient compliance and ease of administration for obesity treatment.

## SEC filing metadata
- accession: 0001558370-24-010964
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837024010964/0001558370-24-010964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837024010964/nrbo-20240806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010964
- JSON: https://secwatch.observer/filing/0001558370-24-010964.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.